drugset / Trial / NCT01241786
Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL
NaSingle-groupOpen-labelTreatment
Summary
To determine the response to the combination of Revlimid (Lenalidomide)+ Vidaza (Azacitidine) in patients with relapsed/refractory CLL and SLL Hypothesis- lenalidomide's activity in combination with azacitidine may further enhance its activity and the durability of treatment response.
Timeline
- Start
- 2010-07
- Primary completion
- 2011-08
- Completion
- 2011-08
Outcome
Outcome not reported
Stopped (Enrollment): “The study was closed early due to poor accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Lenalidomide | Other / unclassified | 5 mg | Oral |